Oculis Holding AG (OCS) Non Operating Income (2022 - 2026)
Oculis Holding AG (OCS) posted quarterly Non Operating Income of -$9.2 million for Q1 2026, up 37.34% year-over-year from -$6.7 million in Q1 2025, and down 140.65% quarter-over-quarter from -$3.8 million in Q4 2025.
Oculis Holding AG (OCS) Non Operating Income (2022 - 2026) Analysis & Trends
Oculis Holding AG's Non Operating Income history runs 5 years deep, the most recent figure standing at -$9.2 million for Q1 2026.
- In Q1 2026, Non Operating Income rose 37.34% year-over-year to -$9.2 million; the TTM figure through Mar 2026 stood at $6.9 billion (up 387.62% YoY), while the FY2025 annual figure was -$21.1 million, down 45.59% from the prior year.
- Non Operating Income for Q1 2026 stood at -$9.2 million, down from -$3.8 million in the prior quarter.
- The five-year high for Non Operating Income was $6.9 billion in Q3 2025, with the low at -$2.4 billion in Q3 2024.
- The 5-year median for Non Operating Income is -$3.2 million (2022), against an average of $278.5 million.
- The sharpest annual moves came in 2024 and 2025: Non Operating Income slumped 45430.84% in 2024, then soared 391.6% in 2025.
- Oculis Holding AG's Non Operating Income stood at $944599.9 in 2022, then plunged by 139.15% to -$369772.3 in 2023, then tumbled by 3491.22% to -$13.3 million in 2024, then soared by 71.14% to -$3.8 million in 2025, then tumbled by 140.65% to -$9.2 million in 2026.
- Business Quant data shows OCS's Non Operating Income at -$9.2 million in Q1 2026, -$3.8 million in Q4 2025, and $6.9 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Oculis Holding AG | 879.09 Mn | 590.21 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.22 Mn |
| Dec 31, 2025 | -3.83 Mn |
| Sep 30, 2025 | 6.87 Bn |
| Jun 30, 2025 | -5.59 Mn |
| Mar 31, 2025 | -14.72 Mn |
| Dec 31, 2024 | -13.28 Mn |
| Sep 30, 2024 | -2.36 Bn |
| Jun 30, 2024 | 1.85 Mn |
| Mar 31, 2024 | -1.90 Mn |
| Dec 31, 2023 | -369,772.27 |
| Sep 30, 2023 | -5.17 Mn |
| Jun 30, 2023 | -2.24 Mn |
| Mar 31, 2023 | 2.19 Mn |
| Dec 31, 2022 | 944,599.94 |
| Sep 30, 2022 | -3.18 Mn |
| Jun 30, 2022 | -3.18 Mn |